how does semaglutide reduce cardiovascular risk New Science Suggests Improves CV Outcomes Beyond Weight Loss GLP-1 Agonists in Cardiovascular Diseases:

These medications represent one component of cardiovascular risk management, not a standalone solution

It is not yet known if medications in the GLP-1 family will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people

Immunity 57, 13941412.e8

The 2025 review also reported that in a large retrospective study of 461,328 adults initiating GLP-1 therapy, over 22% developed at least one nutritional deficiency within 12 months, with vitamin D the most common deficiency identified

Ages ranged from 18 to 80, with an average age of 54, a median income of $83,000 per year, and a male-to-female ratio of 46:54

Unlike single-pathway GLP-1 receptor agonists, Mazdutide engages complementary mechanisms influencing appetite suppression and metabolic rate regulation